Many drugs targeting various components of TME have been approved for clinical therapy, including aromatase, vascular endothelial growth factor (VEGF), and immune checkpoint inhibitors (ICIs), which gained outstanding achievements in the treatment of NSCLC.20 The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.